Ocean Biomedical Inc
oceanbiomedical.comWhat Do They Do?
Develops drug candidates for cancer, fibrosis and infectious diseases using research licensed from universities and medical centers.
10-K for FY2024, filed Apr 8, 2025We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient…View ↗
In oncology, our product candidates are based on Dr. Elias’ findings that a protein called chitinase 3-like-1, or Chi3L1, is a key driver…View ↗
Our product candidate in fibrosis is based on a drug target investigated by Dr. Elias and closely related to the Chi3l1 oncology target…View ↗
In infectious diseases we are developing therapeutic and vaccine candidates against malaria, a mosquito-borne disease that kills 500,000…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2024, filed Apr 8, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 15, 2025
−$8.2MView ↗
- ▼ Now a loss
- vs $13M in Q1 FY2024
-
Aug 5, 2025
Nasdaq delisting became final and the CFO resigned
Sources
8-K, filed Aug 5, 2025
On July 31, 2025, the Company was notified by Nasdaq that The Nasdaq Stock Market LLC Board of Directors has declined to call for review…View ↗
-
Jul 16, 2025
Elkurt terminated licenses covering university and hospital research
Sources
8-K, filed Jul 16, 2025
On July 10, 2025, Ocean Biomedical, Inc. (the “Company”) received final notice from Elkurt, Inc. of termination of the licenses described…View ↗
-
Apr 23, 2025
Company announced expansion into power and cryptocurrency strategies
It plans to develop power assets and allocate part of cash reserves to Bitcoin and Solana.
Sources
8-K, filed Apr 23, 2025
PROVIDENCE, R.I., April 22, 2025 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on…View ↗
From blank-check company to drug developer
The older report described a blank-check company seeking a business combination, with initial targets in pharmaceuticals and medical devices. The latest report describes a biopharmaceutical company licensing university and medical-center discoveries and developing drug candidates.
10-K for FY2021, filed Jan 31, 2022 10-K for FY2024, filed Apr 8, 2025We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient…View ↗
Loading...
